Kurita and his colleagues have demonstrated that TRIP13 involves in CRC cell proliferation and invasion and may be a potential target for CRC treatment8, but they only confirmed the oncogenic role of TRIP13 in vitro, and the mRNA level of TRIP13 was analyzed between normal and tumor tissues from unpaired patients. The gene discussed is TRIP13; the disease is colorectal carcinoma.